- Dr. Chae-Yong Kim of Seoul National College Bundang Sanatorium delivers oral presentation on interim data from 10 enrolled patients
- A manageable security profile, with extended illness build watch over and tumor recurrence inhibition noticed in several patients
SEONGNAM and SEOUL, South Korea, June 15, 2026 /PRNewswire/ — Rznomics Inc., a biopharmaceutical firm specializing within the approach of RNA-based completely mostly gene therapies, announced that the Section 1/2a interim medical results for ‘RZ-001 (Taspitimagene advec)’, its RNA modifying-based completely mostly anticancer gene treatment for recurrent glioblastoma (rGBM), had been provided on June Thirteenth on the Asian Society for Neuro-Oncology Annual Assembly (ASNO 2026) held in Kanazawa, Japan.
The presentation used to be delivered by Dr. Chae-Yong Kim, a professor of the Division of Neurosurgery at Seoul National College Bundang Sanatorium, highlighting the protection and preliminary efficacy data from the ongoing medical trial.
RZ-001 is an innovative anticancer gene treatment utilizing Rznomics’ proprietary RNA trans-splicing ribozyme platform, engineered to explicit a therapeutic gene namely inner tumor cells to induce cancer cell death. In accordance with the presentation, 20 patients hold performed screening to date, with 10 patients officially enrolled and handled within the trial.
The interim analysis printed that no original or surprising treatment-linked security concerns hold been identified. No dose-limiting toxicity (DLT) used to be reported, and no treatment-linked Grade 4 or greater detrimental occasions had been noticed. Most reported detrimental occasions had been deemed to be illness-linked or linked to underlying prerequisites accepted of glioblastoma patients. Furthermore, several patients demonstrated extended tumor recurrence inhibition and illness build watch over exceeding six months.
Recurrent glioblastoma is judicious one of basically the most aggressive and intractable malignant mind tumors, infamous for excessive recurrence rates and an extraordinarily unfortunate prognosis even after usual-of-care treatments. With at this time accredited treatment alternate choices exhibiting restricted efficacy and aged immuno-oncology therapies regularly going by medical screw ups, rGBM represents an deliver with sizable unmet medical wants for unique therapeutic mechanisms.
“The secured data present a manageable security profile for RZ-001 alongside encouraging preliminary indicators of medical process,” defined Dr. Chae-Yong Kim. “On condition that recurrent glioblastoma normally recurs inner two to four months, the information from patients exhibiting long-timeframe recurrence inhibition—in particular that of extending past 9 months—is highly encouraging. We no longer sleep for further clarifying its stout medical tag by further affected person enrollment and long-timeframe apply-up observations.”
In the interim, RZ-001 is at this time undergoing medical trend for every recurrent glioblastoma and hepatocellular carcinoma (HCC). The HCC program now no longer too long ago completed a predominant milestone by receiving Regenerative Treatment Developed Therapy (RMAT) designation from the U.S. FDA this past Would possibly per chance per chance additionally.
About Rznomics Inc.
Rznomics is a medical-stage biopharmaceutical firm based completely mostly in South Korea centered on rising RNA-based completely mostly gene therapies. The firm’s proprietary trans-splicing ribozyme platform permits exact RNA modifying and has colossal applicability throughout more than one indications. The firm signed a study collaboration and license settlement with global pharmaceutical firm Eli Lilly in Would possibly per chance per chance additionally 2025 for the approach of a novel RNA modifying therapeutic and listed on the KOSDAQ market in December 2025. (KOSDAQ 476830)
For more recordsdata, please consult with www.rznomics.com
Glimpse normal impart to download multimedia: https://www.prnewswire.com/news-releases/rznomics-items-medical-interim-data-for-rz-001-in-recurrent-glioblastoma-at-asno-2026-302799942.html
SOURCE Rznomics
